- $22.07m
- $1.32m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.79 | ||
| Price to Tang. Book | 1.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -106.37% | ||
| Return on Equity | -388.29% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.36 | 11.24 | 3.89 | n/a | n/a | n/a | 25 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Directors
- Mark Iwicki CHM (54)
- Todd Bazemore PRE (51)
- Mary Reumuth CFO (46)
- Hongming Chen CSO (50)
- Eric Trachtenberg CCO (48)
- Kim Brazzell OTH (68)
- Andrew Koven LED (63)
- Mark Blumenkranz DRC (68)
- C. Daniel Myers DRC (67)
- Gregory Grunberg IND (48)
- Robert Paull IND (44)
- Gregory Perry IND (60)
- Howard Rosen IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 7th, 2009
- Public Since
- July 20th, 2017
- No. of Shareholders
- 25
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,452,398
- Address
- 1167 Massachusetts Avenue, ARLINGTON, 02476
- Web
- https://www.kalarx.com/
- Phone
- +1 7819965252
- Contact
- Hannah Deresiewicz
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KALA
Q2 2025 KALA BIO Inc Earnings Release
Q3 2025 KALA BIO Inc Earnings Release
Similar to KALA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the KALA BIO share price?
As of Today at 21:30 UTC, shares in KALA BIO are trading at $3.42. This share price information is delayed by 15 minutes.
How has the KALA BIO share price performed this year?
Shares in KALA BIO last closed at $3.42 and the price had moved by -49.05% over the past 365 days. In terms of relative price strength the KALA BIO share price has underperformed the S&P500 Index by -52.99% over the past year.
What are the analyst and broker recommendations for KALA BIO?
The overall consensus recommendation for KALA BIO is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the KALA BIO dividend yield?
KALA BIO does not currently pay a dividend.
Does KALA BIO pay a dividend?
KALA BIO does not currently pay a dividend.
When does KALA BIO next pay dividends?
KALA BIO does not currently pay a dividend.
How do I buy KALA BIO shares?
To buy shares in KALA BIO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of KALA BIO?
As of the previous close price of $3.42, shares in KALA BIO had a market capitalisation of $22.07m.
Where are KALA BIO shares listed?
Here are the trading details for KALA BIO:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KALA
What kind of share is KALA BIO?
Based on an overall assessment of its quality, value and momentum KALA BIO is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a KALA BIO share price forecast for 2025?
The analyst consensus target price for shares in KALA BIO is $15.00. That is 338.6% above the last closing price of $3.42.
Analysts covering KALA BIO currently have a consensus Earnings Per Share (EPS) forecast of -$6.39 for the next financial year.
Find out moreWhat is the trend in the KALA BIO share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like KALA BIO. Over the past six months, its share price has underperformed the S&P500 Index by -52.47%.
As of the last closing price of $3.42, shares in KALA BIO were trading -45.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the KALA BIO PE Ratio?
The KALA BIO PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of KALA BIO?
KALA BIO's management team is headed by:
- Mark Iwicki - CHM
- Todd Bazemore - PRE
- Mary Reumuth - CFO
- Hongming Chen - CSO
- Eric Trachtenberg - CCO
- Kim Brazzell - OTH
- Andrew Koven - LED
- Mark Blumenkranz - DRC
- C. Daniel Myers - DRC
- Gregory Grunberg - IND
- Robert Paull - IND
- Gregory Perry - IND
- Howard Rosen - IND